PRESS RELEASE published on 04/04/2023 at 14:45, 3 years 1 month ago The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
PRESS RELEASE published on 03/23/2023 at 21:30, 3 years 1 month ago Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
PRESS RELEASE published on 03/16/2023 at 21:10, 3 years 2 months ago Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
PRESS RELEASE published on 03/15/2023 at 13:10, 3 years 2 months ago Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
PRESS RELEASE published on 02/10/2023 at 15:00, 3 years 3 months ago Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
PRESS RELEASE published on 02/01/2023 at 14:15, 3 years 3 months ago Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
PRESS RELEASE published on 01/17/2023 at 14:30, 3 years 4 months ago Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Published on 05/23/2026 at 03:15, 52 minutes ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 hour 7 minutes ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 hour 42 minutes ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 hour 42 minutes ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 01:00, 3 hours 7 minutes ago LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Published on 05/22/2026 at 22:05, 6 hours 2 minutes ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 8 hours 16 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 9 hours 34 minutes ago Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 9 hours 37 minutes ago Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Published on 05/22/2026 at 18:05, 10 hours 2 minutes ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 15 hours 14 minutes ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 19 hours 37 minutes ago Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:45, 1 day 10 hours ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
